Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Champions Oncology, Inc.NASDAQ: CSBR
Deferred Revenue · Q3 FY2026 · quarter ended Jan 2026
Deferred revenue falls 8.5% from a year ago
Deferred revenue stood at $10M at the end of Q3 FY2026, down 8.5% from a year earlier and down 19.0% from the prior quarter. Over 3 fiscal years it compounded at +11.7% a year.
Context
- Deferred revenue amounted to 35.1% of total assets at the end of Q3 FY2026, down 0.5 pp from a year earlier.
- Deferred revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -8.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 15.44M USD
- Year-over-year change
- +27.7%
- 4-year CAGR
- +25.3%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 15.44M | +27.7% |
| FY2024 | 2024-04-30 | 12.09M | -5.3% |
| FY2023 | 2023-04-30 | 12.78M | +15.4% |
| FY2022 | 2022-04-30 | 11.07M | +77.0% |
| FY2021 | 2021-04-30 | 6.26M | — |
Deferred Revenue vs competitors
How CSBR compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -8.5% is the 2nd highest of 4, against a peer median of -86.4%.
- Deferred revenue amounts to 35.1% of total assets for CSBR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jan 2026 | $10M USD | -8.5% | +11.7% | 35.1% | |
| Mar 2026 | $9.4M USD | -86.4% | -14.3% | 3.9% | |
| Mar 2026 | $1.47M USD | — | +0.3% | 0.5% | |
| Mar 2026 | $684K USD | -95.7% | -55.3% | 3.4% | |
| Dec 2025 | $167K USD | +1.8% | — | 0.3% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | €0 EUR | — | — | 0.0% | |
IMAImageneBio Inc | Mar 2026 | $0 USD | — | — | 0.0% |
KLRSKalaris Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding CSBR) | — | -86.4% | -14.3% | 0.0% | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.69M | 9.01M | 10.12M | 2.62M | 9.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 6.99M | 9.51M | 8.01M | 9.53M | 11.23M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 1.33M | 1.5M | 1.35M |
| Total Current Assets | 12.63M | 19.66M | 19.46M | 13.64M | 22.37M |
| Property, Plant & Equipment (Net) | 14.61M | 15.36M | 14.5M | 11.97M | 9.46M |
| Goodwill | 335K | 335K | 335K | 335K | 335K |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 15K | 15K | 15K | 185K | 185K |
| Total Non-current Assets | 14.96M | 15.71M | 14.85M | 12.49M | 9.98M |
| Total Assets | 27.59M | 35.38M | 34.31M | 26.13M | 32.34M |
| Account Payables | 1.89M | 2.87M | 5.33M | 5.8M | 4.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6.26M | 11.07M | 12.78M | 12.09M | 15.44M |
| Other Current Liabilities | 0 | 72K | 145K | 150K | 135K |
| Total Current Liabilities | 11.2M | 17.48M | 21.73M | 21.54M | 23.85M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 181K | 391K | 551K | 401K | 85K |
| Total Non-current Liabilities | 8.96M | 8.8M | 7.94M | 6.49M | 4.72M |
| Total Liabilities | 20.16M | 26.28M | 29.68M | 28.04M | 28.57M |
| Common Stock | 13K | 14K | 14K | 14K | 14K |
| Retained Earnings | (72.53M) | (71.98M) | (77.32M) | (84.59M) | (79.89M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.43M | 9.1M | 4.64M | (1.9M) | 3.77M |
| Total Debt | 9.6M | 9.47M | 8.6M | 7.43M | 6.11M |
| Net Debt | 4.91M | 459K | (1.52M) | 4.81M | (3.68M) |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.